#SFHS2607765ADecree of 26 March 2026 Amending the List of Pharmaceutical Specialties Reimbursable to Social Insured Persons
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree adds Imurel 50 mg (azathioprine) film-coated tablets (CIP code 34009 490 058 4 0, pack of 100, manufactured by DIFARMED SLU) to the list of medicines reimbursable by French social security. The patient's co-payment is fully suppressed under Article R. 160-8 of the Social Security Code. Reimbursement is limited exclusively to the therapeutic indications listed in the product's Marketing Authorization (AMM) as of the publication date. The measure takes effect on the fourth day after official publication in the Journal Officiel.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Addition of Imurel 50 mg (azathioprine) CIP 34009 490 058 4 0 (B/100 tablets) to the reimbursable list
- Complete suppression of patient co-payment under first paragraph of Article R. 160-8 of the Social Security Code
- Reimbursement restricted exclusively to therapeutic indications listed in the Marketing Authorization at date of publication
+ 2 more changes with Pro
Obligations
What this law requires
Add Imurel 50 mg (azathioprine) film-coated tablets with CIP code 34009 490 058 4 0 (pack of 100, manufactured by DIFARMED SLU) to the list of reimbursable pharmaceutical specialties
Fully suppress patient co-payment for Imurel 50 mg under Article R. 160-8 of the Social Security Code
Limit reimbursement of Imurel 50 mg exclusively to therapeutic indications listed in the product's Marketing Authorization (AMM) as of the decree publication date
Publish this decree in the Journal Officiel de la République française
Apply the decree effective four days after official publication in the Journal Officiel